جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

13 مُخرَج نتائج البحث عن «Fatty liver»

مراجعةوصول مفتوح2026

Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies

Frontiers in Pharmacology · مجلد 17 · 1822157-1822157

Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.

empagliflozinnon-alcoholic fatty liver diseaseSGLT2 inhibitorshepatic steatosis
مقالوصول مفتوح20254استشهاد· Semantic Scholar

Telmisartan targets Nrf2-HO1 axis in MASLD modulating oxidative stress, inflammation, and mitochondrial dysfunction: mechanistic insights

Libyan Journal of Medicine · مجلد 20 (1) · 2585617-2585617

Metabolically dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide, driven primarily by metabolic derangement. The current investigation proposes to elucidate the hepatoprotective mechanisms of telmisartan (TEL) in MASLD. Twenty-four male Wistar rats were allocated to four groups (Control, MASLD, TEL-treated, and MASLD/TEL). Lipid profiles, glycemic markers, liver enzymes, and hepatic markers of oxidative stress (malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase) were measured. MASLD-associated genes retrieved from GeneCards® were mapped to Rattus norvegicus ortholog genes using the gprofiler2 R package. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analyses were subsequently performed using the clusterProfiler R package. Hepatic inflammatory cytokines (TNF-β, IL-6, and NF-κB), mitochondrial respiratory enzymes (Complexes I–IV), and the gene expression of Nrf2, HO-1, MMP-9, and TIMP-1 were evaluated using spectrophotometric assays for mitochondrial respiratory enzymes. Histological assessment was done using Hematoxylin and Eosin (H&E) staining, Masson's trichrome, and TGF-β immunostaining. TEL ameliorates MASLD-associated disturbances in the serum ALT level and lipid profile. It significantly reduces the levels of oxidative stress markers. KEGG and Reactome enrichment highlighted pathways involved in lipid metabolism, insulin resistance, and inflammation, with the peroxisome proliferator–activated receptor (PPAR) and AMP-activated protein kinase (AMPK) signaling pathways being the most enriched. TEL treatment increased the hepatic expression of Nrf2, HO-1, and TIMP−1 while decreasing the expression of MMP-9. The levels of the proinflammatory cytokines TNF-α and IL-6 decreased. The activities of mitochondrial enzymes (citrate synthase and complex I) improved. MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions.

telmisartannon-alcoholic fatty liver diseaseNrf2/HO-1 pathwayoxidative stress
مقالمفتوح (مستودع)20254استشهاد· Semantic Scholar

Precision Modulation of Gut Microbiome via Metagenomic-driven Dietary and Probiotic Interventions for Non-alcoholic Fatty Liver Disease Management in Obese Saudis

Journal of Advanced Trends in Medical Research · مجلد 2 (3) · 596-601

Background: Non-alcoholic fatty liver disease (NAFLD) is one of the causes of chronic liver diseases. Inconsistency in the microbiome population of individual guts and host–microbial interactions leads to low response in dietary and pharmacological-based treatments. This study aimed to develop and evaluate a metagenomic-guided, culturally adapted dietary and probiotic intervention to reduce hepatic fat and improve metabolic outcomes in obese Saudi adults with NAFLD. Materials and Methods: We combined gut metagenomic analysis, machine learning-based diet modelling and tailored probiotic supplementation to create an intervention platform. Probiotic specificity depends on functional deficits in bacteria participating in specific metabolic pathways, particularly bile acid metabolism. This technique supplements medication with microbiome-based drug processing. Results: At week 24, magnetic resonance imaging–proton density fat fraction (MRI-PDFF) decreased by −3.4 ± 2.2% (control), −8.9 ± 3.1% (diet) and −12.3 ± 3.8% (diet + probiotics); liver fat reduction was significant (analysis of variance (ANOVA) P = 0.0004). In the combined intervention, Faecalibacterium prausnitzii increased 2.3-fold (P = 0.003), faecal butyrate rose from 28.7 ± 4.1 to 45.2 ± 5.6 μmol/g (P = 0.002), faecal deoxycholic acid (fDCA) fell 34% (P = 0.010) with a rise in ursodeoxycholic acid (UDCA) (P = 0.015) and high-sensitivity C-reactive protein declined 42% (6.4 ± 1.7 to 3.7 ± 1.3 mg/L) versus 18% in controls (between-group P = 0.0008). Conclusion: Our precision-guided approach is a novel, scalable solution to managing NAFLD, leveraging the alignment of interactions between hosts, the microbiome and diet within a cultural context. The framework has the potential to optimise therapeutic response in high-risk Saudi communities, and the individual modulation of microbiomes on metabolic diseases is highlighted.

non-alcoholic fatty liver diseasegut microbiotaobesityprobiotic supplementation
مراجعةوصول مفتوح20254استشهاد· Semantic Scholar

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Trials

Cureus · مجلد 17 (6) · e86232-e86232

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with type 2 diabetes mellitus (T2DM), contributing to increased liver-related complications and cardiovascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential treatments offering benefits for both metabolic and liver-related outcomes. This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The review was conducted using a structured methodology, including systematic database searches and risk of bias assessments. Included randomized controlled trials (RCTs) investigated various SGLT2 inhibitors, such as dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin. Most studies showed significant reductions in liver fat content, improvements in serum liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), and favorable effects on blood pressure, triglycerides, and body composition. Glycemic control markers, including glycated hemoglobin (HbA1c), fasting glucose, and insulin resistance indices, also improved. One biopsy-based study demonstrated histological improvements, including reduced fibrosis and resolution of nonalcoholic steatohepatitis (NASH). No serious adverse events were reported. These findings suggest SGLT2 inhibitors may offer dual benefits for managing both diabetes and fatty liver disease. Further long-term studies focusing on liver histology as a primary endpoint are needed to confirm these effects.

SGLT2 inhibitorstype 2 diabetesnon-alcoholic fatty liver diseasedapagliflozin
مقالوصول مفتوح20253استشهاد· Semantic Scholar

Evaluating liver type fatty acid binding protein as a diagnostic and prognostic biomarker in metabolic dysfunction-associated steatotic liver disease in pediatric patients

PLoS ONE · مجلد 20 (9) · e0333581-e0333581

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD), is a common liver disorder, predicted to increase globally. Currently, non-invasive methods are proposed for the assessment of (MASLD). This study aimed to investigate the use of serum Liver Type Fatty Acid Binding Protein (L-FABP) concentration as a diagnostic and prognostic biomarker in pediatric MASLD patients and to evaluate its relationship with steatosis and fibrosis. METHODS: An observational, cross-sectional study on paediatric MASLD patients. Serum levels of L-FABP and hepatic biochemical markers were measured and analyzed. Statistical analyses evaluated the association between L-FABP and other markers, while logistic regression and ROC curves assessed its diagnostic accuracy. RESULTS: Serum L-FABP levels showed a significant difference between the MASLD and control groups (P < 0.0001). The results of logistic regression revealed that each one-unit elevation of L-FABP level was associated with 144.5% higher odds of being MASLD (95% CI: 129.3% - 167.8%). A receiver operating characteristics (ROC) curve was constructed to assess the diagnostic accuracy of L-FABP. The resulted area under the ROC curve (AUC) was 0.885. The cutoff value was 5.7 ng/ mL, with sensitivity of 72.73%, and a specificity of 93.62%. The results also showed that the odds ratio of progressing from stage F2 to F3 increases by 108.9% (95% CI: 87.2% - 141.4%) for each one-unit increase in serum L-FABP level. CONCLUSION: L-FABP shows promise as a non-invasive biomarker for diagnosing and monitoring MASLD in pediatric patients. Its association with disease stages suggests its utility in assessing disease progression, particularly in advanced stages.

liver fatty acid binding proteinnon-alcoholic fatty liver diseasepediatric patientsnon-invasive biomarkers
مقالوصول مفتوح202310استشهاد· Semantic Scholar

Vagal Stimulation Ameliorates Non-Alcoholic Fatty Liver Disease in Rats

Biomedicines · مجلد 11 (12) · 3255-3255

BACKGROUND: The harmful consequences of non-alcoholic fatty liver disease (NAFLD) are posing an increasing threat to public health as the incidence of diabetes and obesity increases globally. A non-invasive treatment with a range of autonomic and metabolic benefits is transcutaneous vagus nerve stimulation (tVNS). AIM OF THE STUDY: To investigate the possible preventive impacts of VNS against adult rats' NAFLD caused by a high-fat diet (HFD) and to clarify the underlying mechanisms. METHODS: = 8). VNS was delivered for 30 min per day for 6 weeks after the establishment of NAFLD using a digital TENS device. The subsequent assessments included hepatic triglyceride, cholesterol content, serum lipid profile, and liver function testing. In this context, inflammatory biomarkers (TNF-α, IL-6) and hepatic oxidative stress (MDA, SOD, and GPx) were also assessed. To clarify the possible mechanisms behind the protective benefits of VNS, additional histological inspection and immunohistochemistry analysis of TNF-α and Caspase-3 were performed. RESULTS: In the NAFLD-affected obese rats, VNS markedly decreased the rats' body mass index (BMI) and abdominal circumference (AC). Liver function markers (albumin, ALT, and AST) and the serum lipid profile-which included a notable decrease in the amounts of hepatic triglycerides and cholesterol-were both markedly improved. Additionally, oxidative stress and inflammatory indicators showed a considerable decline with VNS. Notably, the liver tissues examined by histopathologists revealed that there is evidence of the protective impact of VNS on the oxidative and inflammatory states linked to HFD-induced NAFLD while maintaining the architectural and functional condition of the liver. CONCLUSIONS: Our findings suggest that VNS may represent a promising therapeutic candidate for managing NAFLD induced by obesity. It can be considered to be an effective adjuvant physiological intervention for the obese population with NAFLD to spare the liver against obesity-induced deleterious injury.

non-alcoholic fatty liver diseasetranscutaneous vagus nerve stimulationhigh-fat dietobesity
مقالوصول مفتوح20229استشهاد· Semantic Scholar

Rho-Kinase Inhibition Ameliorates Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Rats

Physiological Research · مجلد 71 (5) · 615-630

Non-alcoholic fatty liver disease (NAFLD) is linked to type 2 diabetes mellitus (T2DM), obesity, and insulin resistance. The Rho/ROCK pathway had been involved in the pathophysiology of diabetic complications. This study was designed to assess the possible protective impacts of the Rho/Rho-associated coiled-coil containing protein kinase (Rho/ROCK) inhibitor fasudil against NAFLD in T2DM rats trying to elucidate the underlying mechanisms. Animals were assigned into control rats, non-treated diabetic rats with NAFLD, and diabetic rats with NAFLD that received fasudil treatment (10 mg/kg per day) for 6 weeks. The anthropometric measures and biochemical analyses were performed to assess metabolic and liver function changes. The inflammatory and oxidative stress markers and the histopathology of rat liver tissues were also investigated. Groups with T2DM showed increased body weight, serum glucose, and insulin resistance. They exhibited disturbed lipid profile, enhancement of inflammatory cytokines, and deterioration of liver function. Fasudil administration reduced body weight, insulin resistance, and raised liver enzymes. It improved the disturbed lipid profile and attenuated liver inflammation. Moreover, it slowed down the progression of high fat diet (HFD)-induced liver injury and reduced the caspase-3 expression. The present study demonstrated beneficial amelioration effect of fasudil on NAFLD in T2DM. The mechanisms underlying these impacts are improving dyslipidemia, attenuating oxidative stress, downregulated inflammation, improving mitochondrial architecture, and inhibiting apoptosis.

non-alcoholic fatty liver diseasetype 2 diabetesfasudilRho/ROCK signaling
مقالمفتوح (مستودع)2022

Review on Pulmonary Embolism Diagnosis and Management Approach

World Journal of Environmental Biosciences · مجلد 11 (3) · 45-49

A frequent illness, pulmonary embolism can cause considerable morbidity and mortality. Certain inherited and acquired risk factors predispose vulnerable individuals, and the clinical situation can arouse suspicion. Studies involving people who had non-alcoholic fatty liver disease were sought after in the Medline, Pubmed, Embase, NCBI, and Cochrane databases. Analysis was done on incidence, etiology, and treatment options. Because PE presents differently in each patient, it is important to take

pulmonary embolismdiagnosismanagementrisk factors
مقالمفتوح (مستودع)202113استشهاد· Semantic Scholar

Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study

Saudi Journal of Biological Sciences · مجلد 28 (9) · 4921-4925

BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) in Saudi Arabia is predicted to exceed 30% by 2030. NAFLD leads to liver fibrosis, thus increasing morbidity and health care burden. Obesity and diabetes have been strongly associated with NAFLD in different cities in Saudi Arabia. OBJECTIVES: Therefore, we aim to determine the prevalence rate of NAFLD and specific risk factors for NAFLD among patients of tertiary care hospital of Taif city. MATERIAL AND METHODS: We retrospectively analyzed the medical records of patients for two years, between Feb 2017 and Feb 2019, (n = 100) referred to the hepatology clinic at King Abdulaziz Specialist Hospital in Taif. The diagnosis of NAFLD was based on the radiology report for patients who were aged >20 years old. Other parameters including fasting blood glucose (FBG), platelets count, alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin were statistically analyzed. RESULTS: We found that 40% (P < 0.05) of all patients had NAFLD. The results revealed that a significantly high number of patients with NAFLD have high FBG levels (75%, P < 0.0001) and total bilirubin (P < 0.05). Meanwhile, platelet count was significantly reduced in patients with NAFLD (P < 0.05). CONCLUSION: NAFLD can be a serious health problem in the Taif region. In addition, high FBG is a significant specific risk factor for NAFLD. Health care providers should pay more attention to limiting the prevalence of NAFLD and its risk factors.

non-alcoholic fatty liver diseaseprevalencerisk factorsfasting blood glucose
مقالمفتوح (مستودع)2019

IRISIN: A POTENTIAL PROMISING AGENT AGAINST NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETIC RATS

Al-Azhar Medical Journal · مجلد 48 (3) · 207-226

Background: Non-alcoholic fatty liver disease (NAFLD) is strongly related to obesity, insulin resistance and type 2 diabetes.Irisin is an exercise-induced myokine which improves glucose profile and insulin resistance. Objective: To evaluate the potential effects of irisin on liver function in type 2 diabetic rats with NAFLD and elucidate the underlying mechanisms. Material and methods: Thirty adult male albino rats were divided into 3equal groups: control rats, type 2 diabetic with NAFLD rats, and type II diabetic rats with NAFLD received irisin (0.5 μg/g body weight once daily for 8 weeks). Diabetes was induced by high fat diet for 12 weeks followed by injection of small dose of streptozotocin (35 mg/kg body weight). Eight weeks after establishment of diabetes, body mass index and abdominal circumference were estimated. Serum was analysed for glucolipid metabolic parameters, liver enzymes, C-reactive protein, tumour necrosis facror-α. Liver homogenate was assayed for malondialdehyde, superoxide dismutase, and glutathione s-transferase activities. Liver sections were stained with Hematoxlyin & eosin. Results: Irisin treatment significantly improved glucolipid metabolic parameters, liver enzymes, antioxidante enzymes accompanied by significant decrease in inflammatory mediators and malondialdehyde levels, with improvement of the histopathological findings. Conclusion: Irisin may be used as a promising agent against NAFLD in type 2 diabetic rats possibly through controlling glucose and lipid metabolism and via its beneficial anti-inflammatory and anti-oxidant effects as well.

irisinnon-alcoholic fatty liver diseasetype 2 diabetesmyokines
مقالوصول مفتوح20181استشهاد

Non-alcoholic fatty liver disease and thyroid function in adult patients

International Journal of Community Medicine and Public Health · مجلد 5 (7) · 2616-2616

Results from published studies on the association between non-alcoholic fatty liver disease and hypothyroidism are still controversial. Thyroid dysfunction is closely related with components of metabolic syndrome. We conducted this meta-analysis using a comprehensive search of EMBASE, MEDLINE, PubMed, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials till 31 January 2018 for prospective observational studies that evaluated the relationship of non-alcoholic fatty liver disease and thyroid function in adult patients. Thirteen studies were included in the present meta-analysis. Meta-analysis of the 13 studies found a high correlation between hypothyroidism and NAFLD (OR=1.48, 95% CI 1.22–1.91, p<0.001). In the meta-regression analyses, we found that study design was a possible source of heterogeneity (p=0.17), but other covariates were not. The present meta-analysis provides strong epidemiological evidence for the relationship between hypothyroidism and NAFLD. Both individuals with subclinical and overt hypothyroidism are at higher risk for NAFLD than euthyroid subjects.

non-alcoholic fatty liver diseasehypothyroidismthyroid functionmetabolic syndrome